PPARGC1A and metabolic dysfunction-associated steatotic liver disease: In this study, we examined the preferential recruitment of four representative coactivator peptides (PGC1α, CBP, SRC1, and TRAP220) to human PPARα/δ/γ-ligand-binding domains (LBDs) by eight PPAR dual/pan agonists (bezafibrate, fenofibric acid, pemafibrate, pioglitazone, elafibranor, lanifibranor, saroglitazar, and seladelpar), all of which are expected to have activity in NAFLD [7].